10-QPeriod: Q2 FY2004

Edwards Lifesciences Corp Quarterly Report for Q2 Ended Jun 30, 2004

Filed August 6, 2004For Securities:EW

Summary

Edwards Lifesciences Corp. (EW) reported its second quarter 2004 financial results, showing a net loss of $36.6 million for the six-month period ended June 30, 2004, a significant change from the $35.6 million net income reported in the same period of 2003. This loss was largely driven by an $81.0 million charge for purchased in-process research and development related to the acquisition of Percutaneous Valve Technologies, Inc. (PVT) in January 2004, and an additional $12.3 million in special charges. Despite the net loss, the company demonstrated revenue growth, with total net sales increasing by 7.7% to $234.6 million for the quarter and 9.1% to $469.6 million for the six-month period, year-over-year. The Heart Valve Therapy and Critical Care segments were key drivers of this revenue growth. The company also secured a new five-year, $500 million revolving credit agreement during the quarter, enhancing its liquidity. Operationally, the company saw improvements in gross profit margin to 60.6% for the quarter, up from 58.9% in the prior year, attributed to expiring currency hedging contracts and a reduction in lower-margin business. SG&A expenses increased but as a percentage of net sales, it slightly decreased due to improved sales in key segments. R&D expenses rose, largely due to investments in percutaneous valve programs and amortization of acquired intangibles. Investors should note the significant impact of the PVT acquisition on earnings, while recognizing the underlying revenue growth and strategic investments in promising technologies. The company's cash position decreased by $21.1 million during the six months, ending at $40.0 million, but overall liquidity appears managed with the new credit facility.

Key Highlights

  • 1Reported a net loss of $36.6 million for the six months ended June 30, 2004, primarily due to an $81.0 million charge for purchased in-process R&D from the PVT acquisition and $12.3 million in special charges.
  • 2Total net sales increased by 7.7% to $234.6 million in the second quarter and 9.1% to $469.6 million for the first six months of 2004, year-over-year.
  • 3Heart Valve Therapy segment sales grew 13.8% for the quarter and 14.7% for the six-month period, driven by strong performance of PERIMOUNT valves.
  • 4Critical Care segment sales increased by 10.0% for the quarter and 11.5% for the six-month period.
  • 5Gross profit margin improved to 60.6% for the quarter, up from 58.9% in the prior year, reflecting improved operational efficiency and changes in product mix.
  • 6Secured a new five-year, $500 million unsecured revolving credit agreement, enhancing financial flexibility and liquidity.
  • 7Cash and cash equivalents decreased by $21.1 million to $40.0 million during the six-month period, with net cash used in investing activities significantly higher due to acquisitions.

Frequently Asked Questions

The company reported a net loss of $36.6 million for the six months ended June 30, 2004, primarily due to an $81.0 million charge for purchased in-process research and development related to the acquisition of Percutaneous Valve Technologies, Inc. (PVT) and $12.3 million in special charges.

The acquisition of PVT in January 2004 significantly impacted the financials by contributing $81.0 million to purchased in-process R&D expenses, leading to the net loss for the six-month period. The company also incurred $125.0 million in cash for the acquisition, plus potential milestone payments.

The main revenue drivers are the Heart Valve Therapy and Critical Care segments, which showed strong growth in the reported periods. Heart Valve Therapy sales increased by 13.8% in the quarter and 14.7% for the six months, while Critical Care sales grew by 10.0% and 11.5%, respectively.

The company replaced its revolving credit agreement with a new five-year, $500 million facility on June 28, 2004, enhancing its liquidity. As of June 30, 2004, $162.8 million was outstanding under this new agreement. The company also utilizes securitization programs for accounts receivable.